The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Upadacitinib Promising for RA Patients

Upadacitinib Promising for RA Patients

July 23, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Recent research examined the use of upadacitinib (ABT-494) in patients with moderate to severe rheumatoid arthritis (RA) who had an inadequate response to conventional disease-modifying anti-rheumatic drugs (csDMARDs). This study was a double-blind, placebo-controlled, phase 3 clinical trial.1

You Might Also Like
  • Upadacitinib Promising for RA in Phase 3 Study
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Meets Study Endpoints to Treat RA
Also By This Author
  • Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

During period 1 of the study, patients (N=661) were randomized to receive once daily, extended-release upadacitinib in 15 mg or 30 mg doses, or placebo for 12 weeks. The primary efficacy endpoints were the proportion of patients who achieved an ACR20 response and the proportion of patients who achieved a DAS28-CRP low disease activity (LDA) score of ≤3.2 at Week 12. At baseline, demographics and disease characteristics were similar among the treatment groups. Ninety-four percent of randomized patients (n=618) completed period 1.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

All of the study’s primary and secondary endpoints were met for both upadacitinib doses. At Week 12, significantly more 15 mg and 30 mg upadacitinib-treated patients achieved an ACR20 response (64% and 66%, respectively) compared with placebo-treated patients (36%, P<0.001). Additionally, the DAS28-CRP LDA scores of less than 3.2 were 48%, 48% and 17%, respectively (P<0.001).

The onset of action for upadacitinib was fast. Significantly more upadacitinib-treated patients achieved an ACR20 response at Week 1 compared with placebo-treated patients. At Week 12, significantly more upadacitinib-treated patients met ACR50 and ACR70 responses compared with placebo-treated patients. Results were 38% (ACR50) and 21% (ACR70) for 15 mg upadacitinib, and 15% (ACR50) for placebo and 43% (ACR50) and 27% (ACR70) for 30 mg upadacitinib and 6% (ACR70) for placebo. Additionally, more upadacitinib-treated patients achieved DAS28-CRP <2.6 and CDAI-LDA (P<0.001) compared with placebo-treated patients. Both doses of upadacitinib had significantly (P<0.001) greater DAS28-CRP, HAQ-DI, morning stiffness and FACIT-F improvements compared with placebo-treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Adverse events occurred in more upadacitinib-treated than placebo-treated patients, with a higher incidence of infections. Four cases of varicella zoster virus infection were reported, with one case in a placebo-treated patient. Asymptomatic CPK elevations occurred in 2.3–2.7% of upadacitinib-treated patients. Two malignancies and three cardiovascular events were reported during the study. No deaths, gastrointestinal perforations or cases of tuberculosis were reported. No instances of pulmonary embolism/deep vein thrombosis were reported.

The tolerability and safety of upadacitinib were consistent with observations from phase 2 clinical trials.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Burmester G, Kremer J, van den Bosch F, et al. A phase 3 randomized, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective jak-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs (OP0036). Ann Rheum Dis. 2018 Jun;77:68–69.

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Rheumatoid Arthritis (RA), upadacitinib

You Might Also Like:
  • Upadacitinib Promising for RA in Phase 3 Study
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Meets Study Endpoints to Treat RA
  • Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.